Stocktoria
ALUMIS INC. ALMS
ALUMIS INC. (ALMS) earns a Piotroski F-score of 1/9 (weak financial health), with an Altman Z″ in the distress zone. It does not currently pay a dividend. FY2025 revenue was $24.1M at a -1011.7% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Analyst price target
Recent analyst actions
| Date | Firm | Rating |
|---|---|---|
| 2026-05-19 | Chardan Capital | Buy (main) |
| 2026-05-15 | Wells Fargo | Overweight (main) |
| 2026-05-15 | Guggenheim | Buy (main) |
| 2026-05-15 | HC Wainwright & Co. | Neutral (down) |
| 2026-03-30 | Oppenheimer | Outperform (main) |
| 2026-03-30 | Chardan Capital | Buy (main) |
Wall Street analyst consensus — a sentiment gauge, not our scoring.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 1/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · distress zone
| Component | Value |
|---|---|
| Working capital / assets | 0.595 |
| Retained earnings / assets | -2.189 |
| EBIT / assets | -1.102 |
| Equity / liabilities | 2.723 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| ALMS | ALUMIS INC. | 1/9 | -7.78 | — | — |
| TRDA | Entrada Therapeutics, Inc. | 2/9 | 4.24 | — | -87.9% |
| NAMS | NewAmsterdam Pharma Co N.V. | 2/9 | 8.19 | — | -50.6% |
| CELU | Celularity Inc | 1/9 | — | — | -51% |
| CUE | Cue Biopharma, Inc. | 4/9 | — | — | — |
| SCYX | SCYNEXIS INC | 4/9 | -13.88 | — | — |
| SLGL | Sol-Gel Technologies Ltd. | 5/9 | -19.59 | — | +68% |
About ALUMIS INC.
Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company offers envudeucitinib, a tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor that is in Phase 1 for the treatment of neuroinflammatory and neurodegenerative diseases. It also develops lonigutamab, a monoclonal antibody targeting IGF-1R for the treatment of thyroid eye diseases; and interferon regulatory factor 5 (IRF5) to address immune dysfunction. The company was formerly known as Esker Therapeutics, Inc. and changed its name to Alumis Inc. in January 2022. Alumis Inc. was incorporated in 2021 and is headquartered in South San Francisco, California.
FAQ
Is ALMS financially healthy?
ALUMIS INC.'s Piotroski F-score is 1/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the distress zone.
Does ALMS pay a dividend?
No, ALUMIS INC. does not currently pay a dividend.
How profitable is ALMS?
In FY2025, ALUMIS INC. had a net margin of -1011.7% and a return on equity of -80.8%.
What is the analyst price target for ALMS?
The average Wall-Street price target for ALUMIS INC. is $40.10, about 56.9% above the recent price, from 10 analysts (consensus: strong buy).
Is ALMS a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on ALUMIS INC.: a Piotroski F-score of 1/9, an Altman Z″ in the distress zone. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.